...
首页> 外文期刊>Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research >Final-2 targeted glycolysis mediated apoptosis and autophagy in human lung adenocarcinoma cells but failed to inhibit xenograft in nude mice
【24h】

Final-2 targeted glycolysis mediated apoptosis and autophagy in human lung adenocarcinoma cells but failed to inhibit xenograft in nude mice

机译:最终-2靶向糖酵解介导的人肺腺癌细胞介导的凋亡和自噬,但未能抑制裸鼠的异种移植物

获取原文
获取原文并翻译 | 示例
           

摘要

Natural products derived from fruits have multiple antitumor potential. However, very few have been developed for clinical therapy, due to the limited efficiency or insufficient study of their mechanism. Since lung cancer is the most common cancer in the world, there is still need to explore novel compounds but their molecular mechanisms remain elusive. In this study, a new compound Final-2 was synthesized. Final-2 exhibited antitumor activity in A549 cells by promoting apoptosis and blocking autophagy. Moreover, Final-2 significantly induced G(0)/G(1) cycle arrest and inhibited cell malignancy. Intracellular molecular targets investigation showed that Final-2 inhibited the Gluts, which resulted in downregulation of glucose metabolism and the oncogene c-Myc and Kras expression in vitro. However, according the autophagy inhibitor CQ and Kras inhibitors test, low concentration of Final-2 showed some controversial effects. In A549 xenograft mice model, 10 mg/kg and 20 mg/kg of Final-2 showed no and partial tumor inhibition, respectively. Moreover, a high dose of Final-2 induced serious liver necrosis. Therefore, the results indicated that even though Final-2 was efficient in suppressing the cancer cell growth in vitro, it failed to inhibit tumors in vivo and showed significant liver toxicity, which was its limitation as a potential antitumor drug.
机译:来自水果的天然产物具有多种抗肿瘤潜力。然而,由于效率有限或对其机制的研究不足,已经开发了很少的临床治疗。由于肺癌是世界上最常见的癌症,仍有需要探索新化的化合物,但它们的分子机制仍然难以捉摸。在该研究中,合成了一种新的复合体最终2。通过促进细胞凋亡和阻断自噬,最终-2在A549细胞中表现出抗肿瘤活性。此外,最终-2最终诱导的G(0)/ g(1)循环滞留和抑制细胞恶性肿瘤。细胞内分子靶标研究表明,最终2抑制了葡萄糖代谢和体外癌基因C-MYC和KRA表达的下降。然而,根据自噬抑制剂CQ和KRAS抑制剂测试,低浓度的最终-2显示出一些有争议的效果。在A549异种移植小鼠模型中,10mg / kg和20mg / kg的最终2分别显示NO和部分肿瘤抑制。此外,高剂量的最终-2诱导严重的肝脏坏死。因此,结果表明,即使最终2在体外抑制癌细胞生长时,它也没有抑制体内肿瘤并显示出显着的肝脏毒性,这是其作为潜在抗肿瘤药物的限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号